Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 26;9(2):122–131. doi: 10.1002/acn3.51492

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

The drug that achieved the best MGFA‐PIS status (improved, minimal manifestations, or remission) for each patient is represented in percentages for the total of drug‐refractory patients, and broken down based on the immunological profile (anti‐acetylcholine receptor‐positive patients, anti‐muscle‐specific tyrosine kinase‐positive patients, and seronegative patients). MG, myasthenia gravis; anti‐AChR, anti‐acetylcholine receptor; anti‐MuSK, anti‐muscle‐specific tyrosine kinase. [Colour figure can be viewed at wileyonlinelibrary.com]